Treating Patients with SCLC with Driver Mutations

Data from DeLLphi-304 support tarlatamab as a preferable second-line therapy for patients with small cell lung cancer.

Experts from Washington University in St. Louis discuss prior data and strategies for mitigating toxicities like CRS associated with tarlatamab in SCLC.

Select adverse effects examined during the initial 24 weeks of treatment occurred at a rare or occasional frequency and mild-to-moderate severity.

Practices are on the cusp of better understanding small cell lung cancer that in turn can help to advance treatment strategies for patients, says Gregory Peter Kalemkerian, MD.

The phase 3 IMforte trial evaluating lurbinectedin plus atezolizumab is the first to show PFS and OS improvement with first-line maintenance for ES-SCLC.